drugset / Trial / NCT00343486

Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms

NCT00343486

Phase 2 Completed 240 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will test the effectiveness and safety of two doses of solabegron against placebo in reducing the symptoms of overactive bladder.

Timeline

Start
2006-05
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Solabegron Unknown 50 mg Oral
Subject Solabegron Unknown 125 mg Oral

Indications